Primary Immunodeficiency Diseases and Immunoglobulin Therapy

Target Audience: Nurses

Program Goal

To enhance the knowledge of the nurse clinican by providing an update on primary immunodeficiency disease and immunoglobulin therapy by defining the differences between intravenous immunoglobulin therapy (IVIG) and subcutaneous immunoglobulin therapy (SCIG) and the nurse's role with these therapies.

Participants will learn to:

1. Describe the spectrum of disease presentation for primary immunodeficiency (PIDD)
2. Discuss the most common PIDD-humoral antibody deficiency
3. Identify the treatments used within the most common PIDD-humoral antibody deficiency
4. Understand the use of IVIG for treatment of PIDD
5. Understand the use of SCIG for treatment of PIDD
6. Describe the differences between IVIG and SCIG
7. Understand the clinician’s role with SCIG

Presentations and Presenters

Overview of Ig Therapy and Disease States in which it is Utilized
Jordan Orange, MD, PhD
Associate Professor of Pediatrics
Division of Allergy and Immunology
University of Pennsylvania School of Medicine
Children’s Hospital of Philadelphia
Philadelphia, PA

Primary Immunodeficiencies Combined T-cell and/or B-cell Immune Defects
Mark Ballow, MD
Division of Allergy, Immunology and Pediatric Rheumatology
Women and Children's Hospital of Buffalo
SUNY Buffalo
School of Medicine and Biomedical Sciences
Buffalo, NY

Intravenous Immunoglobulin Therapy (IVIG)
Kristin Epland, MSN, FNP-C
Midwest Immunology Clinic
Plymouth, MN

Subcutaneous Immunoglobulin Therapy (SCIG)
M. Elizabeth Younger, CRNP, PhD
Johns Hopkins University
Baltimore, MD

Solution Sight, Inc. is accredited as a provider of continuing nursing education by the Amercan Nurses Credentialing Center's Commission on Accreditation. SolutionSight, Inc. is approved by the California Board of Registered Nursing, Provider #CEP 14624. The licensee must retain this Statement of Credit for four years after conclusion of the activity.

This online course for nurses was made possible through an unrestricted educational grant from CSL Behring.